Business Description
Legend Biotech Corp
NAICS : 541714
SIC : 2834
ISIN : US52490G1022
Share Class Description:
STU:9LB: ADRTotal Employee Number:
2,900Description
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 2.14 | |||||
Equity-to-Asset | 0.61 | |||||
Debt-to-Equity | 0.4 | |||||
Debt-to-EBITDA | -2.22 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 4.04 | |||||
Beneish M-Score | -2.53 | |||||
WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 96.5 | |||||
3-Year EBITDA Growth Rate | 21.6 | |||||
3-Year EPS without NRI Growth Rate | 58.6 | |||||
3-Year FCF Growth Rate | 20.8 | |||||
3-Year Book Growth Rate | 6.3 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 27.24 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 25.92 | |||||
9-Day RSI | 36.3 | |||||
14-Day RSI | 42.57 | |||||
3-1 Month Momentum % | 85.62 | |||||
6-1 Month Momentum % | 47.92 | |||||
12-1 Month Momentum % | -5.96 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.13 | |||||
Quick Ratio | 2.05 | |||||
Cash Ratio | 1.64 | |||||
Days Inventory | 23.47 | |||||
Days Sales Outstanding | 2.82 | |||||
Days Payable | 55.74 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -3.9 | |||||
Shareholder Yield % | -0.95 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 54.99 | |||||
Operating Margin % | -11.92 | |||||
Net Margin % | -21.97 | |||||
EBITDA Margin % | -15.4 | |||||
FCF Margin % | -10.24 | |||||
OCF Margin % | -7.25 | |||||
ROE % | -24.85 | |||||
ROA % | -14.98 | |||||
ROIC % | -21.16 | |||||
3-Year ROIIC % | 61.07 | |||||
ROC (Joel Greenblatt) % | -69.34 | |||||
ROCE % | -17.12 | |||||
Moat Score | 6 | |||||
Tariff Resilience Score | 4 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 283.52 | |||||
PS Ratio | 4.49 | |||||
PB Ratio | 5.31 | |||||
Price-to-Tangible-Book | 5.5 | |||||
EV-to-EBIT | -22.84 | |||||
EV-to-Forward-EBIT | 6.88 | |||||
EV-to-EBITDA | -27.97 | |||||
EV-to-Forward-EBITDA | 6.68 | |||||
EV-to-Revenue | 4.31 | |||||
EV-to-Forward-Revenue | 3.37 | |||||
EV-to-FCF | -42.35 | |||||
Price-to-GF-Value | 0.28 | |||||
| Price-to-Net-Current-Asset-Value | 11.32 | |||||
| Price-to-Net-Cash | 25 | |||||
Earnings Yield (Greenblatt) % | -4.38 | |||||
FCF Yield % | -2.16 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return %
Total Annual Return %
Legend Biotech Corp Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 978.717 | ||
| EPS (TTM) (€) | -1.173 | ||
| Beta | 0.6041 | ||
| 3-Year Sharpe Ratio | -0.44 | ||
| 3-Year Sortino Ratio | -0.62 | ||
| Volatility % | 57.62 | ||
| 14-Day RSI | 42.57 | ||
| 14-Day ATR (€) | 1.306438 | ||
| 20-Day SMA (€) | 26.76 | ||
| 12-1 Month Momentum % | -5.96 | ||
| 52-Week Range (€) | 13.7 - 37.8 | ||
| Shares Outstanding (Mil) | 193.44 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Legend Biotech Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Legend Biotech Corp Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-12 08:00 | In 128 days | ||
| Third quarter earnings results for 2026 | 2026-11-12 | In 127 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-11 08:00 | In 35 days | ||
| Second quarter earnings results for 2026 | 2026-08-11 | In 34 days | ||
| General meeting for 2026 | 2026-07-10 09:00 | In 3 days | ||
| ASCO Investor and Analyst Event | 2026-05-31 18:00 | 23.20 (-4.13%) | ||
| First quarter earnings conference call for 2026 | 2026-05-12 08:00 | 21.60 (-8.47%) | ||
| First quarter earnings results for 2026 | 2026-05-12 | 21.60 (-8.47%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-03-10 08:00 | 16.40 (+4.46%) | ||
| Annual report for 2025 | 2026-03-10 | 16.40 (+4.46%) |
Show
Entries
Legend Biotech Corp Frequently Asked Questions
What is Legend Biotech Corp(STU:9LB)'s stock price today?
The current price of STU:9LB is €24.00. The 52 week high of STU:9LB is €37.80 and 52 week low is €13.70.
When is next earnings date of Legend Biotech Corp(STU:9LB)?
The next earnings date of Legend Biotech Corp(STU:9LB) is 2026-08-11 Est..
Does Legend Biotech Corp(STU:9LB) pay dividends? If so, how much?
Legend Biotech Corp(STU:9LB) does not pay dividend.
Press Release
Articles on Legend Biotech Corp
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers